optimal mapk inhibition as a key component of therapeutic strategies for kras mutant cancers
Published 5 years ago • 204 plays • Length 33:37Download video MP4
Download video MP3
Similar videos
-
33:37
optimal mapk inhibition as a key component of therapeutic strategies for kras mutant cancers
-
47:45
resistance in braf and kras mutant cancers - by ryan corcoran, md, phd
-
47:43
emerging therapies to optimize map kinase blockade and intercept compensatory signaling
-
5:23
potential synergy of mek /pd-l1 inhibitors in kras-mutant mcrc
-
45:21
ras oncoproteins therapeutic vulnerabilities
-
6:10
inhibition of mek to treat cancer: focus on melanoma
-
2:38
key lung cancer updates: kras(g12c) inhibitors and adcs
-
3:17
mechanisms of resistance to kras g12c inhibitors
-
26:09
how to improve on the outcome in ras mutant tumors
-
21:11
resistance to mapk pathway inhibition in braf mutant colorectal cancers
-
5:16
the design of novel benzimidazoles as k ras inhibitors for cancer chemotherapy
-
33:47
towards robust and systematic translational systems for cancer therapeutic development
-
0:35
data on kras inhibitors in lung cancer at wclc 2022
-
32:30
braf: the first prevalent oncogene target to show single-agent responsiveness
-
8:47
innovations within precision oncology: evolution of a biomarker—a case study of kras g12c
-
1:07:06
mpccc precision oncology seminar sean grimmond
-
1:07
the case for separating g12d mutations in studying kras-mutant pdac
-
5:16
mitigating resistance in kras-driven cancers
-
6:30
testing for kras mutations in nsclc